 Pre-Exposure Prophylaxis
"Pre-Exposure Prophylaxis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent.
| Descriptor ID |
D065129
|
| MeSH Number(s) |
N02.421.726.758.655 N06.850.780.680.655
|
| Concept/Terms |
Pre-Exposure Prophylaxis- Pre-Exposure Prophylaxis
- Pre Exposure Prophylaxis
- Pre-Exposure Prophylaxi
- Prophylaxi, Pre-Exposure
- Prophylaxis, Pre-Exposure
- Pre-Exposure Prophylaxis (PrEP)
- Pre Exposure Prophylaxis (PrEP)
- Pre-Exposure Prophylaxi (PrEP)
- Prophylaxi, Pre-Exposure (PrEP)
- Prophylaxis, Pre-Exposure (PrEP)
|
Below are MeSH descriptors whose meaning is more general than "Pre-Exposure Prophylaxis".
Below are MeSH descriptors whose meaning is more specific than "Pre-Exposure Prophylaxis".
This graph shows the total number of publications written about "Pre-Exposure Prophylaxis" by people in this website by year, and whether "Pre-Exposure Prophylaxis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 3 | 1 | 4 | | 2015 | 4 | 2 | 6 | | 2016 | 9 | 0 | 9 | | 2017 | 13 | 2 | 15 | | 2018 | 16 | 5 | 21 | | 2019 | 11 | 5 | 16 | | 2020 | 10 | 4 | 14 | | 2021 | 28 | 2 | 30 | | 2022 | 20 | 0 | 20 | | 2023 | 14 | 0 | 14 | | 2024 | 15 | 1 | 16 | | 2025 | 15 | 2 | 17 | | 2026 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Pre-Exposure Prophylaxis" by people in Profiles.
-
Valentin OR, Henderson C, Coffin LS, Paredes-Gotamco J, Olem D, Farrales W, Neilands TB, Dilworth SE, Doblecki-Lewis S, Page K, Moskowitz JT, Anderson PL, Johnson MO, Carrico AW. Positive psychological intervention to reduce HIV acquisition risk with men who use stimulants: protocol for a randomised controlled trial. BMJ Open. 2026 May 11; 16(5):e120232.
-
Hampanda K, Amstutz A, Nayame L, Sehrt M, Hamoonga T, Menon JA, Mumbula I, Mulawa M, Nkole E, Matenga FJ, Mugode M, Mweemba O. TwySHE-an mHealth peer-navigator intervention to increase PrEP and contraceptive use among female university students in Zambia: study protocol of a hybrid effectiveness-implementation randomized controlled trial. Trials. 2026 Mar 05; 27(1).
-
Mhlanga FG, Szydlo DW, Mayo AJ, Bunge K, Fairlie L, Nakabiito C, Musara P, Mgodi NM, Dadabhai S, Scheckter R, Anderson PL, Marzinke MA, Chappell C, Gadama LA, Richardson BA, Piper JM, Hillier SL. Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial. Lancet HIV. 2026 Mar; 13(3):e176-e184.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Miller SE, Dukes KA, Damato-MacPherson C, Psaros C, Scott NA, Taylor JL, Muroff J, Winter MR, Skiba LE, Lugo H, Cruz R, Ruiz-Mercado G, Crawford ND, Mayer KH, Assoumou SA. Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS?+?randomized controlled trial study protocol. Addict Sci Clin Pract. 2025 12 25; 21(1):17.
-
Abuogi LL, Imran R, Limas A, Moor J, Leonard K, Pierce K, De La Garza AJ, Gallegos S, Duenas J, Littrell Z, Vyas P, Richards M, Straub D, McFarland EJ. Pilot outcomes of a telehealth model for youth PrEP (TelePrEP) among youth at risk for HIV in Colorado. HIV Res Clin Pract. 2025 Dec 31; 26(1):2588009.
-
Cianelli R, De Santis JP, Iriarte E, De Oliveira GC, Williams R, Placide Reaves R, Castro JG, Hodge S, Thomas SO, Edwards C, Baeza Robba MJ, Villegas N, Montano NP. SEPA+PrEP-BW intervention: A feasible and acceptable HIV prevention intervention for Black women. PLoS One. 2025; 20(11):e0336435.
-
Fairlie L, Szydlo DW, Mayo A, Bunge K, Mhlanga F, Piper J, Dadabhai S, Gatsi VM, Horne E, Ssemambo PK, Mandiwa V, Mgodi NM, Owor M, Anderson PL, Marzinke MA, Nakabiito C, Scheckter R, Chappell C, Hillier SL. Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study. Lancet HIV. 2025 Nov; 12(11):e763-e773.
-
Beyrer C, Remien RH, Eshleman SH, Gamble TR, De Dieu Tapsoba J, Labbett RL, Sullivan PA, Laeyendecker O, Anderson PL, Agravat D, Hughes JP, Driffin DD, Hutchinson CS, Hucks-Ortiz C, Adair M, Curry M, Jones SB, Haddock IL, Boyd D, Burwen DR, Johnson AS, Nelson LE. Investigating the HIV epidemic among Black gay and bisexual men in the Southern United States: Results of the HPTN 096 pilot cross-sectional assessment. PLoS One. 2025; 20(10):e0334031.
-
Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|